Notice for amifampridine (ORSPEC Pharma Pty Ltd)
Active ingredients
amifampridine
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Indication
A potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and children aged 6 years and above